![Jeffrey Ravetch](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jeffrey Ravetch
Corporate Officer/Principal bei
The Rockefeller University
Profil
Jeffrey V.
Ravetch is the founder of Rhapsogen, Inc., founded in 2025.
Dr. Ravetch is the founder of Virdante Pharmaceuticals, Inc., founded in 2008.
Dr. Ravetch is the founder of MacroGenics, Inc., founded in 2000.
Dr. Ravetch is also the founder of Nuvig Therapeutics, Inc...
Dr. Ravetch is a Professor at The Rockefeller University since 1997.
Dr. Ravetch is a Member of the National Academy of Sciences since 2006.
Dr. Ravetch is a Member of the National Academy of Medicine (United States) since 2007.
Dr. Ravetch is a Venture Partner at Catalio Capital Management LP.
Dr. Ravetch was a Director at Telik, Inc. Dr. Ravetch was a Director at MabVax Therapeutics, Inc. Dr. Ravetch was a Director at MabVax Therapeutics Holdings, Inc. from 2016 to 2017.
Dr. Ravetch completed undergraduate studies at Yale University in 1973.
Dr. Ravetch earned a doctorate from The Rockefeller University in 1978.
Dr. Ravetch earned a doctorate from Weill Cornell Medical College in 1979.
Aktive Positionen von Jeffrey Ravetch
| Unternehmen | Position | Beginn |
|---|---|---|
The Rockefeller University
 The Rockefeller University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.1997 |
National Academy of Sciences
 National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services Operates as a private, nongovernmental institution that advises on issues related to science and technology | Corporate Officer/Principal | 01.01.2006 |
National Academy of Medicine (United States)
 National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services Operates as a professional membership organization | Corporate Officer/Principal | 01.01.2007 |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Private Equity Investor | - |
Ehemalige bekannte Positionen von Jeffrey Ravetch
| Unternehmen | Position | Ende |
|---|---|---|
| MABVAX THERAPEUTICS HOLDINGS, INC. | Direktor/Vorstandsmitglied | 03.08.2017 |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops translating novel therapeutics medicine for autoimmune diseases | Gründer | - |
Virdante Pharmaceuticals, Inc.
 Virdante Pharmaceuticals, Inc. Medical DistributorsDistribution Services Develops and commercializes drugs | Gründer | - |
MabVax Therapeutics, Inc.
 MabVax Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Developed and commercialized immunotherapeutics for the treatment of cancer | Direktor/Vorstandsmitglied | - |
Ausbildung von Jeffrey Ravetch
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
85
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Telik, Inc.
 Telik, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and commercializing novel small molecule drugs to treat serious diseases | Health Technology |
Virdante Pharmaceuticals, Inc.
Virdante Pharmaceuticals, Inc. Medical DistributorsDistribution Services Develops and commercializes drugs | Distribution Services |
MabVax Therapeutics, Inc.
MabVax Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Developed and commercialized immunotherapeutics for the treatment of cancer | Health Technology |
MacroGenics, Inc.
 MacroGenics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes antibody-based therapeutics for the treatment of cancer | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Rockefeller University
The Rockefeller University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Academy of Sciences
National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services Operates as a private, nongovernmental institution that advises on issues related to science and technology | Commercial Services |
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services Operates as a professional membership organization | Commercial Services |
Weill Cornell Medical College
 Weill Cornell Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MabVax Therapeutics Holdings, Inc.
 MabVax Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes immunotherapeutics for the treatment of cancer | Health Technology |
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Finance |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops translating novel therapeutics medicine for autoimmune diseases | Health Technology |
